Sanofi is battle-ready: "We welcome competition, not least from our great colleagues at Leo Pharma"

French pharmaceutical firm Sanofi has already spun gold within an area that Leo Pharma enters with major drug candidate.

Photo: Benoit Tessier/Reuters/Ritzau Scanpix

French pharmaceutical firm Sanofi has shown the way for the Danish pharmaceutical company Leo Pharma in terms of conquering the market for a new type of treatment for eczema and asthma.

In a few years, the French drug Dupixent has turned into a blockbuster, and in the latest quarter it sold for more than USD 1bn worldwide. This has sent the company's confidence through the roof.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs